Clazosentan
- Generic Name
- Clazosentan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H23N9O6S
- CAS Number
- 180384-56-9
- Unique Ingredient Identifier
- 3DRR0X4728
- Indication
Investigated for use/treatment in strokes.
- Associated Conditions
- -
- Associated Therapies
- -
A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03657446
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan
- Conditions
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03596294
- Locations
- 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
- Conditions
- Interventions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 409
- Registration Number
- NCT03585270
- Locations
- 🇺🇸
University of Illinois - Department of Neurosurgery, Chicago, Illinois, United States
🇺🇸University Hospitals Case Medical Center - Department of Neurosurgery, Cleveland, Ohio, United States
ðŸ‡ðŸ‡ºDebreceni Egyetem, Idegsebészet, Debrecen, Hungary
Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02560532
- Locations
- 🇫🇷
Site 1002, Bron, France
🇫🇷Site 1004, Marseille, France
🇨ðŸ‡Site 3001, Basel, Switzerland
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 1157
- Registration Number
- NCT00558311
- Locations
- 🇩🇪
Thechnical University-Klinikum rechts der Isar, Munich, Germany
🇺🇸State University of New York at Stony Brook-Health Sciences Center, Stony Brook, New York, United States
🇺🇸University of Cincinnati-Department of Neurosurgery, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.